About 858 Therapeutics
858 Therapeutics is a private company based in San Diego, California. It has reported $65,231,597 raised in three offerings on Form D since March 2020.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 26, 2024 | Jul 11, 2024 | $25,175,501of $50.3M target | 12 | $2.0M | EquityRule 506(b) | Form D ↗ |
| May 4, 2021 | May 18, 2021 | $20,000,001of $39.9M target | 6 | $3.3M | EquityRule 506(b) | Form D ↗ |
| Mar 3, 2020 | Mar 11, 2020 | $20,056,095of $37.5M target | 1 | $20.0M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $65,231,597 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on 858 Therapeutics's Form D filed Jul 11, 2024.
JV
James Veal
Executive officer
JH
Jane Huang
Director
MM
Monal Mehta
Director
SJ
Stafford Jeffrey
Executive officer and director
AB
KM
Katherine Bell-McGuinn
Executive officer
CO
Clare Ozawa
Director
Earlier filings also listed Carlo Rizzuto (director, last listed May 2021) and Bradley Bolzon (director, last listed Mar 2020).